Effects of treatment with once-daily nifedipine CR and twice-daily benidipine on prevention of symptomatic attacks in patients with coronary spastic angina pectoris-Adalat Trial vs Coniel in Tokyo against Coronary Spastic Angina (ATTACK CSA)

Journal of Cardiology

Volumn 55, Issue 2, 2010, Pages 238-247

  Oikawa, Yuji ^a   Matsuno, Syunsuke ^a   Yajima, Junji ^a   Nakamura, Masato ^b   Ono, Tsuyoshi ^b   Ishiwata, Sugao ^c   Fujimoto, Yo ^c   Aizawa, Tadanori ^a  

^a THE CARDIOVASCULAR INSTITUTE   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c TORANOMON HOSPITAL   (Japan)

Author keywords

Benidipine; Calcium channel blockers; Coronary spastic angina; Nifedipine CR

Indexed keywords

BENIDIPINE; NIFEDIPINE; NITRIC ACID DERIVATIVE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY SPASM; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HEART RATE; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; JAPAN; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SMOKING; TREATMENT OUTCOME;

ACETYLCHOLINE; ANGINA PECTORIS; BLOOD PRESSURE; CORONARY VASOSPASM; DIHYDROPYRIDINES; ELECTROCARDIOGRAPHY, AMBULATORY; ERGONOVINE; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NIFEDIPINE; NITRATES; VASODILATOR AGENTS;

EID: 77349107375     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2009.11.005     Document Type: Article

References (44)

1. Yasue H., Omote S., Takizawa A., and Nagao M. Coronary arterial spasm in ischemic heart disease and its pathogenesis. A review. Circ Res 52 2 Pt 2 (1983) I147-I152
2. Ogawa H., Yasue H., Oshima S., Okumura K., Matsuyama K., and Obata K. Circadian variation of plasma fibrinopeptide A level in patients with variant angina. Circulation 80 (1989) 1617-1626
3. Soejima H., Irie A., Miyamoto S., Kajiwara I., Kojima S., Hokamaki J., Sakamoto T., Tanaka T., Yoshimura M., Nishimura Y., and Ogawa H. Preference toward a T-helper type 1 response in patients with coronary spastic angina. Circulation 107 (2003) 2196-2200
4. Nakayama M., Yoshimura M., Sakamoto T., Abe K., Yamamuro M., Shono M., Suzuki S., Nishijima T., Miyamoto Y., Saito Y., Nakao K., Yasue H., and Ogawa H. A786T → C polymorphism in the endothelial nitric oxide synthase gene reduces serum nitrite/nitrate levels from the heart due to an intracoronary injection of acetylcholine. Pharmacogenet Genom 16 (2006) 339-345
5. Nakayama M., Yasue H., Yoshimura M., Shimasaki Y., Kugiyama K., Ogawa H., Motoyama T., Saito Y., Ogawa Y., Miyamoto Y., and Nakao K. T-786 → C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99 (1999) 2864-2870
6. Yoshimura M., Yasue H., Nakayama M., Shimasaki Y., Sumida H., Sugiyama S., Kugiyama K., Ogawa H., Ogawa Y., Saito Y., Miyamoto Y., and Nakao K. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 103 (1998) 65-69
7. Tanabe Y., Itoh E., Suzuki K., Ito M., Hosaka Y., Nakagawa I., and Kumakura M. Limited role of coronary angioplasty and stenting in coronary spastic angina with organic stenosis. J Am Coll Cardiol 39 (2002) 1120-1126
8. Fuke S., Maekawa K., Kawamoto K., Saito H., Sato T., Hioka T., and Ohe T. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J 71 (2007) 220-225
9. Togni M., Windecker S., Cocchia R., Wenaweser P., Cook S., Billinger M., Meier B., and Hess O.M. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46 (2005) 231-236
10. Kimura E., and Kishida H. Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan. Circulation 63 (1981) 844-848
11. Ogawa H. Guidelines for diagnosis and treatment of patients with coronary spastic angina (JCS2008). Circ J 72 Suppl. 4 (2008) 38
12. Ito A., Fukumoto Y., and Shimokawa H. Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers. J Cardiovasc Pharmacol 44 (2004) 480-485
13. Sueda S., Oshita A., Izoe Y., Kohno H., and Fukuda H. Investigation of the influential factor in prognosis and the result of medical therapy in patients with coronary spastic angina. J Res Circ 54 (2006) 1255-1261 [in Japanese]
14. Io K., Minatoguchi S., Nishigaki K., Ojio S., Tanaka T., Segawa T., Matsuo H., Watanabe S., Hattori A., Ueno K., Ono H., Hiei K., Sato H., Morita N., Noda T., et al. Effects of benidipine and some other calcium channel blockers on the prognosis of patients with vasospastic angina. Cohort study with evaluation of the ergonovine coronary spasm induction test. Arzneimittelforschung 57 (2007) 573-581
15. Kodama S., Inoue Y., Mihara H., Sumi S., Kudo K., Okamura K., Ando C., Niimura H., Tsuchiya Y., Yamanouchi Y., and Urata H. Prognostic factors for long-term survival in patients with vasospastic angina. Analysis of effects of patients' characteristics and therapeutic drugs. J Cardiol 54 (2009) 10-20
16. Arioka I., Dohi S., Dohi S., and Sakai K. Prognostic effects of calcium channel blockers on cardiac events, stroke and end-stage renal disease in patients with angina pectoris. Retrospective comparative study of benidipine, diltiazem and nifedipine. Arzneimittelforschung 58 (2008) 435-440
17. Fukumoto Y., Yasuda S., Ito A., and Shimokawa H. Prognostic effects of benidipine in patients with vasospastic angina: comparison with diltiazem and amlodipine. J Cardiovasc Pharmacol 51 (2008) 253-257
18. Nakamichi N.Y.T., and Hikima Y. Phase I study of nifedipine sustained-release formulation (BAY a 1040-OD Tablets); single administration study. Jpn Pharmacol Ther 23 Suppl. (1995) 241-255 [in Japanese]
19. Okumura K., Yasue H., Horio Y., Takaoka K., Matsuyama K., Kugiyama K., Fujii H., and Morikami Y. Multivessel coronary spasm in patients with variant angina: a study with intracoronary injection of acetylcholine. Circulation 77 (1988) 535-542
20. Sueda S., Ochi N., Kawada H., Matsuda S., Hayashi Y., Tsuruoka T., and Uraoka T. Frequency of provoked coronary vasospasm in patients undergoing coronary arteriography with spasm provocation test of acetylcholine. Am J Cardiol 83 (1999) 1186-1190
21. Curry Jr. R.C., Pepine C.J., Sabom M.B., and Conti C.R. Similarities of ergonovine-induced and spontaneous attacks of variant angina. Circulation 59 (1979) 307-312
22. Yamada K., Yasui S., Kishida H., Himejima K., Murakami E., Takekoshi N., Yamazaki N., Hirakawa S., Itoh H., Hayashi H., Ogawa K., Toyama J., Mizuno Y., Sotobata I., Watanebe T., et al. Clinical evaluation of benidipine hydrochloride(KW-3049) on angina pectoris-a double-blind comparative study with nifedipine. Ther Res 11 (1990) 1637-1655
23. Kato K., Kishida H., Hiramori K., Nakamura Y., Hosoda S., Iinuma H., Sugimoto T., Katagiri T., Ueda K., Nagata H., Yasuda J., Mizuno Y., Kawai C., Shimomura K., Takeshita A., et al. Clinical evaluation of nifedipine sustained-release formulation (BAY a 1040-OD tablets) on variant form of angina pectoris: double-blind comparative study with nisoldipine. Jap Pharmacol Ther 23 Suppl. (1995) 531-560
24. Yasue H.O.K., Saito T., Takizawa A., and Nobuyoshi M. The clinical effects and the safety of benidipine hydrochloride (KW-3049) in patients with variant angina: evaluation with 24-hour Holter recordings. Yakuri 18 Suppl. (1990) 909-927
25. Sugiishi M., and Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. Circulation 87 (1993) 76-79
26. Yasue H., Nakagawa H., Itoh T., Harada E., and Mizuno Y. Coronary artery spasm-clinical features, diagnosis, pathogenesis, and treatment. J Cardiol 51 (2008) 2-17
27. Yasue H., Takizawa A., Nagao M., Nishida S., Horie M., Kuboto J., Omote S., Takaoka K., and Okumura K. Long-term prognosis for patients with variant angina and influential factors. Circulation 78 (1988) 1-9
28. Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol 17 (1977) 149-166
29. Vater W., Kroneberg G., Hoffmeister F., Saller H., Meng K., Oberdorf A., Puls W., Schlossmann K., and Stoepel K. Pharmacology of 4-(2′-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (Nifedipine, BAY a 1040). Arzneimittelforschung 22 (1972) 1-14
30. Bond B.R., Zellner J.L., Dorman B.H., Multani M.M., Kratz J.M., Crumbley III A.J., Crawford Jr. F.A., and Spinale F.G. Differential effects of calcium channel antagonists in the amelioration of radial artery vasospasm. Ann Thorac Surg 69 (2000) 1035-1040 [discussion 1040-1031]
31. Stern Z., Zylber-Katz E., and Levy M. Nifedipine plasma concentration in patients treated for angina pectoris. Int J Clin Pharmacol Ther Toxicol 22 (1984) 198-203
32. Morikami Y., and Yasue H. Efficacy of slow-release nifedipine on myocardial ischemic episodes in variant angina pectoris. Am J Cardiol 68 (1991) 580-584
33. Heupler Jr. F.A., and Proudfit W.L. Nifedipine therapy for refractory coronary arterial spasm. Am J Cardiol 44 (1979) 798-803
34. Karasawa A., and Kubo K. Calcium antagonistic effects and the in vitro duration of actions of KW-3049, a new 1,4-dihydropyridine derivative, in isolated canine coronary arteries. Jpn J Pharmacol 47 (1988) 35-44
35. Ikeda J., Matsubara M., and Yao K. Effects of benidipine in a rat model for experimental angina. Yakugaku Zasshi 126 (2006) 1377-1381
36. Yamashita T., Kawashima S., Ozaki M., Rikitake Y., Hirase T., Inoue N., Hirata K., and Yokoyama M. A calcium channel blocker, benidipine, inhibits intimal thickening in the carotid artery of mice by increasing nitric oxide production. J Hypertens 19 (2001) 451-458
37. Kitakaze M., Node K., Minamino T., Asanuma H., Kuzuya T., and Hori M. A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs. J Am Coll Cardiol 33 (1999) 242-249
38. Miwa Y., Masai H., and Shimizu M. Differential effects of calcium-channel blockers on vascular endothelial function in patients with coronary spastic angina. Circ J 73 (2009) 713-717
39. Wang N., Minatoguchi S., Chen X.H., Arai M., Uno Y., Lu C., Misao Y., Nagai H., Takemura G., and Fujiwara H. Benidipine reduces myocardial infarct size involving reduction of hydroxyl radicals and production of protein kinase C-dependent nitric oxide in rabbits. J Cardiovasc Pharmacol 43 (2004) 747-757
40. Yui Y., Shinoda E., Kodama K., Hirayama A., Nonogi H., Haze K., Sumiyoshi T., Hosoda S., Kawai C., and Japan Multicenter Investigation for Cardiovascular Diseases B (JMIC-B) Study Group. Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy). J Hypertens 25 (2007) 2019-2026
41. Pristipino C., Beltrame J.F., Finocchiaro M.L., Hattori R., Fujita M., Mongiardo R., Cianflone D., Sanna T., Sasayama S., and Maseri A. Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation 101 (2000) 1102-1108
42. Kitakaze M., Asanuma H., Takashima S., Minamino T., Ueda Y., Sakata Y., Asakura M., Sanada S., Kuzuya T., and Hori M. Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs. Circulation 101 (2000) 311-317
43. Lupo E., Locher R., Weisser B., and Vetter W. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol. Biochem Biophys Res Commun 203 (1994) 1803-1808
44. Matsumori A., Nunokawa Y., and Sasayama S. Nifedipine inhibits activation of transcription factor NF-kappaB. Life Sci 67 (2000) 2655-2661